M&A Deal Summary |
|
|---|---|
| Date | 2015-12-14 |
| Target | IBA Molecular Imaging |
| Sector | Medical Products |
| Buyer(s) | CapVest |
| Sellers(s) |
SK Capital Partners
IBA |
| Deal Type | Secondary Buyout |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 4.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
CapVest is a UK-based private equity firm that targets investments in mid-market businesses across Europe. CapVest focuses on profitable companies with growth potential and strong management. Specific areas of interest include food/beverages (especially frozen food sector), healthcare, real estate, retail, media, hotel/leisure, and telecommunication services. CapVest is affiliated with junior capital investor, MezzVest. CapVest was formed in 1999 and is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 24 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Secondary Buyout M&A Deals | 7 of 16 |
| State: Vermont M&A | 1 of 1 |
| Country: United States M&A | 1 of 3 |
| Year: 2015 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-07-28 |
Valeo Foods
Dublin, Ireland Valeo Foods is a producer and innovator of branded food products including Jacobs, Rowse, Kettle, Odlums, Barratt and Balconi, among others, across various categories and channels. Valeo Foods was founded in 1845 and is based in Dublin, Ireland. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-03-27 |
Karro Food Group
Malton, United Kingdom Karro Food Group is a vertically integrated British pork producer. Karro supplies fresh pork and cured, cooked, and frozen meats to retail, foodservice and manufacturing customers and key export markets including the US and China. Karro Food Group is based in Malton, United Kingdom. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2007 |
| PE ASSETS | 4.9B USD |
| Size | Large |
| Type | Sector Agnostic |
SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 16 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Secondary Buyout M&A Deals | 1 of 2 |
| State: Vermont M&A | 1 of 1 |
| Country: United States M&A | 1 of 11 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-06 |
Cambrex Drug Product- Business Unit
Whippany, New Jersey, United States Cambrex Drug Product's Business Unit is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances. Cambrex Drug Product's Business Unit was established in 2006 and is based in Whippany, New Jersey. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-11 |
Extractas Bioscience
Westbury, Australia Extractas Bioscience is a provider in agricultural R&D and the extraction and purification of high-value plant-derived products, with a particular focus on alkaloid raw materials used in the production of active pharmaceutical ingredients. Extractas Bioscience was founded in 1975 and is based in Westbury, Australia. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Medical Products |
| Employees | 1,943 |
| Revenue | 498M EUR (2024) |
IBA develops innovative solutions by sharing ideas and know-how with customers, partners and leading experts to bring new solutions for the diagnosis and treatment of cancer and for the benefits of patients. IBA was founded in 1986 and is based in Louvain-La-Neuve, Belgium.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Medical Products M&A | 1 of 2 |
| Type: Secondary Buyout M&A Deals | 1 of 1 |
| State: Vermont M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-11-18 |
Cisbio Bioassays SAS
Codolet, France Cisbio Bioassays SAS is a life sciences company committed to improving human healthcare. Cisbio develops and markets products and technologies used for in vitro diagnostics and drug discovery. |
Sell | €25M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-12-17 |
RadioMed
Bartlett, Tennessee, United States RadioMed Corp. is an implantable fiducial marker used for soft tissue tumor localization for enhanced accuracy in radiation therapy planning and delivery. RadioMed Corp. was established in 1997 and is based in Bartlett, Tennessee. |
Sell | - |
